Comparative Pharmacology
Head-to-head clinical analysis: LOCORTEN versus NUTRACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCORTEN versus NUTRACORT.
LOCORTEN vs NUTRACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
Corticosteroid receptor agonist; induces anti-inflammatory proteins and suppresses inflammatory mediators.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
One capsule (200 mg) orally twice daily with meals.
None Documented
None Documented
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Terminal half-life: 2-4 hours (mean 3 hours). Clinically, dosing every 6-8 hours maintains therapeutic levels.
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Renal (primarily as glucuronide and sulfate conjugates, <10% unchanged) and fecal (biliary excretion of metabolites). Approximately 70-80% renal, 20-30% fecal.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid